Bristol-Myers Squibb Rises 0.32 as $450M Volume Places It 241st in U.S. Equity Rankings Amid Strategic Shifts and Regulatory Clarity

. 15, , . equities. The stock's performance was driven by updates in its and regulatory developments in key markets.

. . , .

. , reducing near-term volatility concerns. , , .

To structure this back-test precisely I need to confirm a few details: 1. Market universe • Should the “top-500” list be drawn from all U.S. listed common stocks, or another specific market/universe? 2. Ranking & execution timing • Do we rank by the previous day’s total dollar volume or share volume? • Do we open positions at today’s close (after ranking on today’s data) and exit at tomorrow’s close, or would you prefer open-to-open, or another convention? 3. Transaction costs / slippage • Should we include an assumption for commission or slippage, or treat the trades as frictionless? 4. Price type for the return calculation (open vs close prices). Once these are settled I can generate the retrieval plan, fetch the required data, and run the back-test.